Wednesday, November 5, 2025

Ardena appoints Dipesh Patel as Chief Quality Officer and Peter Rose as Chief Information Officer – reinforcing focus on quality, compliance, and digital integration

Ardena, a leading pharmaceutical CDMO and bioanalytical CRO, has announced the appointment of Dipesh Patel as Chief Quality Officer (CQO) and Peter Rose as Chief Information Officer (CIO). These key appointments further strengthen the executive leadership team and underline Ardena’s dedication to quality, regulatory excellence, and digital transformation across its global network.

Dipesh Patel brings more than 25 years of experience in the pharmaceutical industry, including senior leadership roles at Accord Healthcare and Catalent. As a certified EU Qualified Person (QP), he will lead Ardena’s global Quality and Regulatory organization, enhancing compliance consistency and driving operational excellence across all sites. With a strong academic foundation in Chemistry, Biology, and Toxicology, and extensive regulatory knowledge, he bolsters Ardena’s reputation as a trusted partner for complex pharmaceutical development.

Peter Rose joins Ardena with over 25 years of IT leadership experience across multiple industries, most recently as Global Head of IT Infrastructure and Security at Diversey. Previously, he spent a decade at Catalent overseeing IT systems supporting quality, analytical, and manufacturing operations. At Ardena, he will focus on digital integration, automation, AI advancement, and cybersecurity, driving productivity and collaboration throughout the organization.

Jeremie Trochu, CEO of Ardena, stated:

“These appointments mark an important step in strengthening Ardena’s foundation as we accelerate our global growth and expand the capabilities that enable next-generation precision medicines. Our continued investment in IT integration, digital infrastructure, and quality excellence is driving sustainable productivity and innovation.”

About Ardena:
Ardena is a specialist Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) dedicated to advancing precision medicines. Its integrated solutions support innovative and complex molecules through services in nanomedicine, drug product and substance manufacturing, solid-state chemistry, bioanalytical services, and CMC regulatory support.